Latest From Biotech Now

Oxford Union Debate Remarks


Remarks of BIO CEO Jim Greenwood As prepared for delivery. Oxford Union Debate Oxford, England Thursday, October 20, 2016 Mr. Chairman, thank you for the invitation to be here this evening. It is, indeed, a great honor. For 182 years, the Oxford Union has shown the world what civil discourse looks like. I wish I could say the same about this year’s U.S. presidential campaign. I began my career working with children who had intellectual Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: ,

BIO Investor Forum Celebrates 15th Year with Record Number of Partnering Meetings


The 15th Annual BIO Investor Forum wrapped up in San Francisco yesterday, having exceeded all prior years’ numbers of meetings arranged through the BIO One-on-One Partnering™ system. Both the conference and the partnering system are designed to help investors identify the latest trends and provide biotech innovators an opportunity to secure the funding necessary to bring their technologies to market. This year’s forum brought together over 884 attendees including 240 investors and 155 presenting companies. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Banning GMOs in N.Y. School Lunches Carries a Price


Dr. W. Lesser, Susan E. Lynch Professor in Science and Business at the Dyson School of Applied Economics and Management at Cornell University, recently published a blog arguing that the New York PTA’s proposal to go GMO-free in the State school meals program would come with a hefty financial burden. Dr. Lesser’s piece was published in the Cornell Alliance for Science blog page and an except can be found below: The purpose here is to put a Read More >

Food And Agriculture  |  Leave a comment  |  Email This Post
Tags: , , ,

MassBio Releases Statement Following Cost Trends Hearings


MassBio issues this statement, following the Massachusetts’ Health Policy Commission’s (HPC) hearing earlier this week on the cost and value of health care cost trends. BIO stands with MassBio in our commitment to addressing the true cost and value of innovative medical therapies and their place within cost containment efforts across the entire healthcare system today. Innovation in biopharmaceuticals saves lives. It also saves money. Every reduced hospital stay, every surgery avoided, every inoculation can help reduce Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Benefiting from Innovative Clinical Trial Designs


Clinical trial success rates have been known to be low for some time now, but that does not imply they will remain low forever. As more tools become available to clinical trial sponsors, technical operators and even patients, future clinical success may look nothing like it has over the last decade. Taking steps to change old fashioned protocols were panelist that gathered for today’s panel on clinical trial innovation trends at the BIO Investor Forum Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,